title: Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study.
abstract: OBJECTIVE
  Our aim was to evaluate the long-term effect of cinacalcet in patients with hypercalcaemic secondary hyperparathyroidism (SHPT) after renal transplantation (RT) in order to expand real-world data in this population.
  
  
  METHODS
  We performed a multicentre, observational, retrospective study in 17 renal transplant units from Spain. We collected data from renal recipients with hypercalcaemic (calcium >10.2 mg/dL) SHPT (intact parathyroid hormone (iPTH) > 120 pg/mL) who initiated cinacalcet in the clinical practice.
  
  
  RESULTS
  We included 193 patients with a mean (standard deviation (SD)) age of 52 (12) years, 58% men. Cinacalcet treatment was initiated at a median of 20 months after RT (median dose 30 mg/day). Mean calcium levels decreased from a mean (SD) of 11.1 (0.6) at baseline to 10.1 (0.8) at 6 months (9.0% reduction, P < 0.0001). Median iPTH was reduced by 23.0% at 6 months (P = 0.0005) and mean phosphorus levels increased by 11.1% (P < 0.0001). The effects were maintained up to 3-years. No changes were observed in renal function or anticalcineurin drug levels. Only 4.1% of patients discontinued cinacalcet due to intolerance and 1.0% due to lack of efficacy.
  
  
  CONCLUSIONS
  In renal transplant patients with hypercalcaemic SHPT, cinacalcet controlled serum calcium, iPTH and phosphorus levels up to 3 years. Tolerability was good.
authors.affiliation: Nephrology Service and Renal Transplant Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
authors.forename: Jose-Vicente
authors.initials: JV
authors.lastname: Torregrosa
authors.forename: Enrique
authors.initials: E
authors.lastname: Morales
authors.forename: Juan Manuel
authors.initials: JM
authors.lastname: Díaz
authors.forename: Josep
authors.initials: J
authors.lastname: Crespo
authors.forename: Juan
authors.initials: J
authors.lastname: Bravo
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Gómez
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Gentil
authors.forename: Alberto
authors.initials: A
authors.lastname: Rodríguez Benot
authors.forename: Minerva Rodríguez
authors.initials: MR
authors.lastname: García
authors.forename: Verónica López
authors.initials: VL
authors.lastname: Jiménez
authors.forename: Alex
authors.initials: A
authors.lastname: Gutiérrez Dalmau
authors.forename: Luisa
authors.initials: L
authors.lastname: Jimeno
authors.forename: María José Pérez
authors.initials: MJ
authors.lastname: Sáez
authors.forename: Rafael
authors.initials: R
authors.lastname: Romero
authors.forename: Carlos
authors.initials: C
authors.lastname: Gómez Alamillo
mesh_terms: D000328:Adult; D000368:Aged; D002118:Calcium / Q000097:blood; D000069449:Cinacalcet; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000188:drug therapy*; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D012189:Retrospective Studies
chemical_list: D009281:Naphthalenes; D010281:Parathyroid Hormone; D010758:Phosphorus; D002118:Calcium; D000069449:Cinacalcet
keywords: calcium; cinacalcet; parathyroid hormone; renal transplantation; secondary hyperparathyroidism